Psilocybin group therapy for treatment-resistant depression
Part of Mental health clinical trials.
This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a specific previous trial that tested psilocybin (PSI-1V2 or Psilo-BD).
- You must be willing to attend all group therapy sessions and keep other group members' information private.
- You cannot have active suicidal thoughts or plans.
- You must be able to read and speak English well enough to understand the study materials and take part in group discussions.
- You cannot be receiving psilocybin-assisted therapy elsewhere during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking psilocybin (a psychedelic drug) with trazodone (an antidepressant) can help people whose depression hasn't improved with at least two standard antidepressants. If you have treatment-resistant depression, this study might be an option.
This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
This study tests whether psilocybin (a psychedelic compound) combined with talk therapy can help people who have both major depression and alcohol use disorder. The goal is to see if it can improve mood and reduce drinking.
This trial tests whether a treatment called psilocybin (a hallucinogen that can help with depression) combined with group therapy can improve symptoms of depression. It requires participants to have significant depression symptoms and a support person to drive them home after each session.
Hear when a new Treatment-resistant Depression (TRD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.